Financing supports advancement of late-stage infectious disease pipeline, including Lonafarnib for the treatment of chronic hepatitis D

融资支持后期传染病产品管线的推进，包括用于治疗慢性丁型肝炎的洛那法尼

KIRKLAND, Wash.

华盛顿州柯克兰

,

，

Aug. 31, 2026

2026年8月31日

/PRNewswire/ -- EIT Pharma, Inc. ('EIT Pharma' or the 'Company'), a biotechnology company focused on developing therapies for infectious diseases, today announced the successful close of an oversubscribed $35 million Series A financing round. The round was led by Propel Bio Partners, with participation from Good Ventures, Arrowtown, and others..

/美通社/ -- 专注于开发传染病疗法的生物科技公司 EIT Pharma, Inc.（“EIT Pharma”或“公司”）今日宣布，成功完成超额认购的3500万美元A轮融资。本轮融资由 Propel Bio Partners 领投，Good Ventures、Arrowtown 等机构参与投资。

The financing follows the U.S. Food and Drug Administration's (FDA) acceptance of the New Drug Application (NDA) for lonafarnib for the treatment of chronic hepatitis D (CHD), a serious life-threatening liver disease caused by hepatitis D virus (HDV) in individuals who already have hepatitis B virus infection.

此次融资紧随美国食品药品监督管理局（FDA）受理lonafarnib用于治疗慢性丁型肝炎（CHD）的新药申请（NDA）之后。慢性丁型肝炎是一种由丁型肝炎病毒（HDV）引起的严重且危及生命的肝脏疾病，发生在已感染乙型肝炎病毒的患者身上。

Lonafarnib is an investigational first-in-class oral CHD therapy candidate with a unique mechanism of action. If approved, lonafarnib's oral administration and room-temperature storage may offer practical advantages for people impacted by CHD and healthcare providers who consider quality of life, treatment burden, and accessibility when evaluating treatment options..

洛那法尼是一种在研的首创类口服先天性心脏病（CHD）治疗候选药物，具有独特的作用机制。如果获得批准，洛那法尼的口服给药方式和室温储存条件可能为受先天性心脏病影响的患者以及在选择治疗方案时考虑生活质量、治疗负担和可及性的医疗保健提供者带来实际优势。

Proceeds from the funding will support continued FDA review activities related to lonafarnib, and future manufacturing and commercial readiness steps for lonafarnib, subject to regulatory approval. The funding will also assist with the advancement of EIT Pharma's infectious disease pipeline and general corporate operations..

融资所得将用于支持与lonafarnib相关的FDA持续审评活动，以及在获得监管批准的前提下，推进lonafarnib的未来生产和商业化准备工作。该资金还将助力EIT Pharma传染病产品管线的推进及公司日常运营。

'This oversubscription of this round is a validation of EIT Pharma's founding belief that advancing important medicines is about recognizing unrealized potential and assembling the scientific, clinical, regulatory, and commercial expertise to turn that potential into a treatment for patients,' said Dr.

“本轮超额认购验证了EIT Pharma的创始信念，即推进重要药物研发的关键在于识别未实现的潜力，并整合科学、临床、监管和商业方面的专业知识，将这种潜力转化为患者的治疗方案。”博士说。

Leen Kawas, PhD, Chief Executive Officer of EIT Pharma. 'This new capital allows us to continue advancing lonafarnib through the review process and, subject to FDA approval, prepare to bring it to patients.'.

EIT Pharma 首席执行官 Leen Kawas 博士表示：“这笔新资金使我们能够继续推进 lonafarnib 的审评进程，并在获得美国食品药品监督管理局（FDA）批准的情况下，做好将其提供给患者的准备。”

'EIT Pharma pairs a differentiated, late-stage asset with a team experienced in moving complex programs through development and regulatory review,' said Richard Kayne, General Partner of Propel Bio Partners. 'We see meaningful value potential across EIT Pharma's infectious disease pipeline, and we're backing a management team with the scientific, clinical, and commercial discipline to realize it.

“EIT Pharma 将一款差异化的后期资产与一支在推动复杂项目通过开发和监管审查方面经验丰富的团队相结合，”Propel Bio Partners 普通合伙人 Richard Kayne 表示。“我们看到 EIT Pharma 的传染病管线具有显著的价值潜力，而我们正支持一支具备科学、临床和商业化专业能力以实现这一潜力的管理团队。”

We're proud to support EIT Pharma at this pivotal stage as it works to bring important new therapies to underserved patient communities.'.

我们自豪地在EIT Pharma的关键阶段为其提供支持，助力其为医疗资源不足的患者群体带来重要的新疗法。

About Lonafarnib

关于洛那法尼

Lonafarnib is an investigational oral therapy candidate being evaluated for the treatment of chronic hepatitis D. Lonafarnib is designed to target a key step in the hepatitis D virus lifecycle and is currently the only oral therapeutic candidate in late-stage clinical development for chronic hepatitis D.

Lonafarnib 是一种正在评估用于治疗慢性丁型肝炎的在研口服疗法候选药物。Lonafarnib 旨在靶向丁型肝炎病毒生命周期中的关键步骤，目前是唯一处于后期临床开发阶段的慢性丁型肝炎口服疗法候选药物。

Lonafarnib has not been approved by the U.S. Food and Drug Administration or any other regulatory authority for the treatment of chronic hepatitis D. The safety and efficacy of lonafarnib have not been established..

洛那法尼尚未获得美国食品药品监督管理局或任何其他监管机构批准用于慢性丁型肝炎的治疗。洛那法尼的安全性和有效性尚未确立。

About EIT Pharma, Inc.

关于EIT Pharma, Inc.

EIT Pharma is a biotechnology company focused on advancing therapies for infectious diseases with significant unmet medical needs. The company is developing a portfolio of programs designed to address serious infectious diseases through rigorous science, disciplined execution, and a patient-centered approach focused on translating scientific innovation into meaningful real-world impact for patients..

EIT Pharma 是一家生物技术公司，专注于推进针对存在重大未满足医疗需求的感染性疾病的治疗方案。该公司正在开发一系列项目，旨在通过严谨的科学、严格的执行以及以患者为中心的方法，将科学创新转化为对患者具有实际意义的现实影响，从而应对严重的感染性疾病。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements regarding regulatory review timelines, anticipated milestones, potential product characteristics, and future development plans. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.

本新闻稿包含有关监管审查时间表、预期里程碑、潜在产品特性以及未来开发计划的前瞻性陈述。这些陈述基于当前的预期和假设，并受风险和不确定性的影响，可能导致实际结果出现重大差异。

Lonafarnib is an investigational product candidate and has not been approved by the FDA. There can be no assurance that the FDA will approve the NDA or that the product will become commercially available. EIT undertakes no obligation to update forward-looking statements except as required by law..

Lonafarnib 是一种处于研究阶段的产品候选药物，尚未获得美国食品药品监督管理局（FDA）的批准。无法保证 FDA 会批准该新药申请（NDA），也无法保证该产品将实现商业化供应。除法律要求外，EIT 不承担更新前瞻性陈述的义务。

Media Contact

媒体联系人

Reevemark

Reevemark

Jacqueline Zuhse/Jill Steinman

杰奎琳·祖塞/吉尔·斯坦曼

[email protected]

[email protected]

212-433-4600

212-433-4600

SOURCE EIT Pharma

来源：EIT Pharma

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示